nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—Cytochrome P450 3A Inhibitors—Saquinavir—acquired immunodeficiency syndrome	0.23	0.336	CiPCiCtD
Crizotinib—Cytochrome P450 3A Inhibitors—Lopinavir—acquired immunodeficiency syndrome	0.174	0.255	CiPCiCtD
Crizotinib—P-Glycoprotein Inhibitors—Lopinavir—acquired immunodeficiency syndrome	0.109	0.159	CiPCiCtD
Crizotinib—Cytochrome P450 3A Inhibitors—Ritonavir—acquired immunodeficiency syndrome	0.105	0.154	CiPCiCtD
Crizotinib—P-Glycoprotein Inhibitors—Ritonavir—acquired immunodeficiency syndrome	0.0659	0.0964	CiPCiCtD
Crizotinib—CYP3A5—Nevirapine—acquired immunodeficiency syndrome	0.00969	0.0775	CbGbCtD
Crizotinib—CYP3A5—Delavirdine—acquired immunodeficiency syndrome	0.00876	0.0701	CbGbCtD
Crizotinib—CYP3A5—Amprenavir—acquired immunodeficiency syndrome	0.00876	0.0701	CbGbCtD
Crizotinib—CYP3A5—Indinavir—acquired immunodeficiency syndrome	0.00756	0.0605	CbGbCtD
Crizotinib—CYP3A5—Nelfinavir—acquired immunodeficiency syndrome	0.00734	0.0588	CbGbCtD
Crizotinib—CYP3A5—Saquinavir—acquired immunodeficiency syndrome	0.00664	0.0531	CbGbCtD
Crizotinib—CYP3A5—Ritonavir—acquired immunodeficiency syndrome	0.00664	0.0531	CbGbCtD
Crizotinib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0063	0.0505	CbGbCtD
Crizotinib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0057	0.0456	CbGbCtD
Crizotinib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.00492	0.0394	CbGbCtD
Crizotinib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00478	0.0382	CbGbCtD
Crizotinib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00432	0.0346	CbGbCtD
Crizotinib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00432	0.0346	CbGbCtD
Crizotinib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00414	0.0332	CbGbCtD
Crizotinib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00402	0.0322	CbGbCtD
Crizotinib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.00378	0.0302	CbGbCtD
Crizotinib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.00378	0.0302	CbGbCtD
Crizotinib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00342	0.0273	CbGbCtD
Crizotinib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00342	0.0273	CbGbCtD
Crizotinib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0032	0.0256	CbGbCtD
Crizotinib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00295	0.0236	CbGbCtD
Crizotinib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00286	0.0229	CbGbCtD
Crizotinib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00259	0.0207	CbGbCtD
Crizotinib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00259	0.0207	CbGbCtD
Crizotinib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00248	0.0199	CbGbCtD
Crizotinib—AURKA—Cladribine—Abacavir—acquired immunodeficiency syndrome	0.000339	0.271	CbGdCrCtD
Crizotinib—AURKA—Floxuridine—Zidovudine—acquired immunodeficiency syndrome	0.00031	0.248	CbGdCrCtD
Crizotinib—AURKA—Floxuridine—Stavudine—acquired immunodeficiency syndrome	0.00031	0.248	CbGdCrCtD
Crizotinib—AURKA—Gemcitabine—Lamivudine—acquired immunodeficiency syndrome	0.000152	0.122	CbGdCrCtD
Crizotinib—AURKA—Cytarabine—Lamivudine—acquired immunodeficiency syndrome	0.00014	0.112	CbGdCrCtD
Crizotinib—Visual impairment—Ritonavir—acquired immunodeficiency syndrome	0.000112	0.00151	CcSEcCtD
Crizotinib—Dysgeusia—Efavirenz—acquired immunodeficiency syndrome	0.000112	0.00151	CcSEcCtD
Crizotinib—Anaemia—Indinavir—acquired immunodeficiency syndrome	0.000112	0.0015	CcSEcCtD
Crizotinib—Hypoaesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000112	0.0015	CcSEcCtD
Crizotinib—Body temperature increased—Didanosine—acquired immunodeficiency syndrome	0.000112	0.0015	CcSEcCtD
Crizotinib—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.000111	0.00149	CcSEcCtD
Crizotinib—Urinary tract disorder—Saquinavir—acquired immunodeficiency syndrome	0.000111	0.00148	CcSEcCtD
Crizotinib—Paraesthesia—Nelfinavir—acquired immunodeficiency syndrome	0.00011	0.00148	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.00011	0.00148	CcSEcCtD
Crizotinib—Decreased appetite—Nevirapine—acquired immunodeficiency syndrome	0.00011	0.00148	CcSEcCtD
Crizotinib—Paraesthesia—Stavudine—acquired immunodeficiency syndrome	0.00011	0.00147	CcSEcCtD
Crizotinib—Urethral disorder—Saquinavir—acquired immunodeficiency syndrome	0.00011	0.00147	CcSEcCtD
Crizotinib—Malnutrition—Delavirdine—acquired immunodeficiency syndrome	0.00011	0.00147	CcSEcCtD
Crizotinib—Dyspnoea—Nelfinavir—acquired immunodeficiency syndrome	0.00011	0.00147	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.00011	0.00147	CcSEcCtD
Crizotinib—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.000109	0.00147	CcSEcCtD
Crizotinib—Eye disorder—Ritonavir—acquired immunodeficiency syndrome	0.000109	0.00146	CcSEcCtD
Crizotinib—Syncope—Indinavir—acquired immunodeficiency syndrome	0.000109	0.00146	CcSEcCtD
Crizotinib—Paraesthesia—Abacavir—acquired immunodeficiency syndrome	0.000108	0.00145	CcSEcCtD
Crizotinib—Dyspepsia—Nelfinavir—acquired immunodeficiency syndrome	0.000108	0.00145	CcSEcCtD
Crizotinib—Cardiac disorder—Ritonavir—acquired immunodeficiency syndrome	0.000108	0.00145	CcSEcCtD
Crizotinib—Visual impairment—Saquinavir—acquired immunodeficiency syndrome	0.000108	0.00145	CcSEcCtD
Crizotinib—Vision blurred—Efavirenz—acquired immunodeficiency syndrome	0.000108	0.00145	CcSEcCtD
Crizotinib—Dyspepsia—Stavudine—acquired immunodeficiency syndrome	0.000108	0.00145	CcSEcCtD
Crizotinib—Dyspnoea—Abacavir—acquired immunodeficiency syndrome	0.000108	0.00144	CcSEcCtD
Crizotinib—Dysgeusia—Delavirdine—acquired immunodeficiency syndrome	0.000107	0.00144	CcSEcCtD
Crizotinib—Decreased appetite—Nelfinavir—acquired immunodeficiency syndrome	0.000107	0.00143	CcSEcCtD
Crizotinib—Loss of consciousness—Indinavir—acquired immunodeficiency syndrome	0.000107	0.00143	CcSEcCtD
Crizotinib—Decreased appetite—Stavudine—acquired immunodeficiency syndrome	0.000107	0.00143	CcSEcCtD
Crizotinib—Oedema—Zidovudine—acquired immunodeficiency syndrome	0.000107	0.00143	CcSEcCtD
Crizotinib—Hypoaesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000107	0.00143	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000106	0.00142	CcSEcCtD
Crizotinib—Anaemia—Efavirenz—acquired immunodeficiency syndrome	0.000106	0.00142	CcSEcCtD
Crizotinib—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000106	0.00142	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000106	0.00142	CcSEcCtD
Crizotinib—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.000106	0.00142	CcSEcCtD
Crizotinib—Mediastinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000105	0.00141	CcSEcCtD
Crizotinib—Decreased appetite—Abacavir—acquired immunodeficiency syndrome	0.000105	0.00141	CcSEcCtD
Crizotinib—Eye disorder—Saquinavir—acquired immunodeficiency syndrome	0.000105	0.00141	CcSEcCtD
Crizotinib—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000105	0.0014	CcSEcCtD
Crizotinib—Shock—Zidovudine—acquired immunodeficiency syndrome	0.000105	0.0014	CcSEcCtD
Crizotinib—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.000104	0.0014	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000104	0.0014	CcSEcCtD
Crizotinib—Cardiac disorder—Saquinavir—acquired immunodeficiency syndrome	0.000104	0.0014	CcSEcCtD
Crizotinib—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.000104	0.00139	CcSEcCtD
Crizotinib—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000103	0.00139	CcSEcCtD
Crizotinib—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.000103	0.00139	CcSEcCtD
Crizotinib—Syncope—Efavirenz—acquired immunodeficiency syndrome	0.000103	0.00138	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000103	0.00138	CcSEcCtD
Crizotinib—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	0.000101	0.00136	CcSEcCtD
Crizotinib—Anaemia—Delavirdine—acquired immunodeficiency syndrome	0.000101	0.00136	CcSEcCtD
Crizotinib—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000101	0.00136	CcSEcCtD
Crizotinib—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000101	0.00136	CcSEcCtD
Crizotinib—Loss of consciousness—Efavirenz—acquired immunodeficiency syndrome	0.000101	0.00135	CcSEcCtD
Crizotinib—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.0001	0.00134	CcSEcCtD
Crizotinib—Dysgeusia—Ritonavir—acquired immunodeficiency syndrome	9.94e-05	0.00133	CcSEcCtD
Crizotinib—Oedema—Indinavir—acquired immunodeficiency syndrome	9.91e-05	0.00133	CcSEcCtD
Crizotinib—Vomiting—Amprenavir—acquired immunodeficiency syndrome	9.85e-05	0.00132	CcSEcCtD
Crizotinib—Syncope—Delavirdine—acquired immunodeficiency syndrome	9.84e-05	0.00132	CcSEcCtD
Crizotinib—Leukopenia—Delavirdine—acquired immunodeficiency syndrome	9.82e-05	0.00132	CcSEcCtD
Crizotinib—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	9.77e-05	0.00131	CcSEcCtD
Crizotinib—Rash—Amprenavir—acquired immunodeficiency syndrome	9.77e-05	0.00131	CcSEcCtD
Crizotinib—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	9.76e-05	0.00131	CcSEcCtD
Crizotinib—Shock—Indinavir—acquired immunodeficiency syndrome	9.75e-05	0.00131	CcSEcCtD
Crizotinib—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	9.72e-05	0.0013	CcSEcCtD
Crizotinib—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	9.72e-05	0.0013	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	9.7e-05	0.0013	CcSEcCtD
Crizotinib—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	9.69e-05	0.0013	CcSEcCtD
Crizotinib—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	9.66e-05	0.00129	CcSEcCtD
Crizotinib—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	9.65e-05	0.00129	CcSEcCtD
Crizotinib—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	9.65e-05	0.00129	CcSEcCtD
Crizotinib—Skin disorder—Indinavir—acquired immunodeficiency syndrome	9.62e-05	0.00129	CcSEcCtD
Crizotinib—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	9.57e-05	0.00128	CcSEcCtD
Crizotinib—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	9.57e-05	0.00128	CcSEcCtD
Crizotinib—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	9.56e-05	0.00128	CcSEcCtD
Crizotinib—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	9.55e-05	0.00128	CcSEcCtD
Crizotinib—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	9.5e-05	0.00127	CcSEcCtD
Crizotinib—Anaemia—Ritonavir—acquired immunodeficiency syndrome	9.38e-05	0.00126	CcSEcCtD
Crizotinib—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	9.38e-05	0.00126	CcSEcCtD
Crizotinib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	9.32e-05	0.00125	CcSEcCtD
Crizotinib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	9.26e-05	0.00124	CcSEcCtD
Crizotinib—Shock—Efavirenz—acquired immunodeficiency syndrome	9.21e-05	0.00123	CcSEcCtD
Crizotinib—Nausea—Amprenavir—acquired immunodeficiency syndrome	9.2e-05	0.00123	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	9.2e-05	0.00123	CcSEcCtD
Crizotinib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	9.19e-05	0.00123	CcSEcCtD
Crizotinib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	9.18e-05	0.00123	CcSEcCtD
Crizotinib—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	9.13e-05	0.00122	CcSEcCtD
Crizotinib—Constipation—Zidovudine—acquired immunodeficiency syndrome	9.11e-05	0.00122	CcSEcCtD
Crizotinib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	9.11e-05	0.00122	CcSEcCtD
Crizotinib—Syncope—Ritonavir—acquired immunodeficiency syndrome	9.1e-05	0.00122	CcSEcCtD
Crizotinib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	9.09e-05	0.00122	CcSEcCtD
Crizotinib—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	9.08e-05	0.00122	CcSEcCtD
Crizotinib—Anaemia—Saquinavir—acquired immunodeficiency syndrome	9.03e-05	0.00121	CcSEcCtD
Crizotinib—Vomiting—Didanosine—acquired immunodeficiency syndrome	8.98e-05	0.0012	CcSEcCtD
Crizotinib—Oedema—Delavirdine—acquired immunodeficiency syndrome	8.96e-05	0.0012	CcSEcCtD
Crizotinib—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	8.92e-05	0.0012	CcSEcCtD
Crizotinib—Rash—Didanosine—acquired immunodeficiency syndrome	8.9e-05	0.00119	CcSEcCtD
Crizotinib—Infection—Delavirdine—acquired immunodeficiency syndrome	8.9e-05	0.00119	CcSEcCtD
Crizotinib—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	8.9e-05	0.00119	CcSEcCtD
Crizotinib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	8.89e-05	0.00119	CcSEcCtD
Crizotinib—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	8.83e-05	0.00118	CcSEcCtD
Crizotinib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	8.82e-05	0.00118	CcSEcCtD
Crizotinib—Shock—Delavirdine—acquired immunodeficiency syndrome	8.81e-05	0.00118	CcSEcCtD
Crizotinib—Asthenia—Stavudine—acquired immunodeficiency syndrome	8.79e-05	0.00118	CcSEcCtD
Crizotinib—Syncope—Saquinavir—acquired immunodeficiency syndrome	8.76e-05	0.00117	CcSEcCtD
Crizotinib—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	8.74e-05	0.00117	CcSEcCtD
Crizotinib—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	8.72e-05	0.00117	CcSEcCtD
Crizotinib—MAP3K2—lung—acquired immunodeficiency syndrome	8.7e-05	0.00136	CbGeAlD
Crizotinib—PLK4—lymph node—acquired immunodeficiency syndrome	8.7e-05	0.00136	CbGeAlD
Crizotinib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	8.7e-05	0.00117	CcSEcCtD
Crizotinib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	8.69e-05	0.00116	CcSEcCtD
Crizotinib—EPHA2—blood—acquired immunodeficiency syndrome	8.68e-05	0.00135	CbGeAlD
Crizotinib—RPS6KB1—vagina—acquired immunodeficiency syndrome	8.67e-05	0.00135	CbGeAlD
Crizotinib—Asthenia—Abacavir—acquired immunodeficiency syndrome	8.66e-05	0.00116	CcSEcCtD
Crizotinib—STK4—lymph node—acquired immunodeficiency syndrome	8.65e-05	0.00135	CbGeAlD
Crizotinib—SLK—bone marrow—acquired immunodeficiency syndrome	8.62e-05	0.00135	CbGeAlD
Crizotinib—LCK—vagina—acquired immunodeficiency syndrome	8.62e-05	0.00134	CbGeAlD
Crizotinib—FGR—vagina—acquired immunodeficiency syndrome	8.62e-05	0.00134	CbGeAlD
Crizotinib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	8.61e-05	0.00115	CcSEcCtD
Crizotinib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	8.61e-05	0.00115	CcSEcCtD
Crizotinib—SLK—spinal cord—acquired immunodeficiency syndrome	8.59e-05	0.00134	CbGeAlD
Crizotinib—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	8.59e-05	0.00115	CcSEcCtD
Crizotinib—AXL—vagina—acquired immunodeficiency syndrome	8.58e-05	0.00134	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	8.58e-05	0.00115	CcSEcCtD
Crizotinib—PTK2B—nervous system—acquired immunodeficiency syndrome	8.57e-05	0.00134	CbGeAlD
Crizotinib—EPHB4—bone marrow—acquired immunodeficiency syndrome	8.56e-05	0.00134	CbGeAlD
Crizotinib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	8.55e-05	0.00115	CcSEcCtD
Crizotinib—BMP2K—central nervous system—acquired immunodeficiency syndrome	8.55e-05	0.00133	CbGeAlD
Crizotinib—Fatigue—Indinavir—acquired immunodeficiency syndrome	8.54e-05	0.00114	CcSEcCtD
Crizotinib—CYP3A5—blood plasma—acquired immunodeficiency syndrome	8.53e-05	0.00133	CbGeAlD
Crizotinib—EPHB4—spinal cord—acquired immunodeficiency syndrome	8.53e-05	0.00133	CbGeAlD
Crizotinib—PTK2—lung—acquired immunodeficiency syndrome	8.52e-05	0.00133	CbGeAlD
Crizotinib—TBK1—lung—acquired immunodeficiency syndrome	8.52e-05	0.00133	CbGeAlD
Crizotinib—JAK2—bone marrow—acquired immunodeficiency syndrome	8.5e-05	0.00133	CbGeAlD
Crizotinib—Constipation—Indinavir—acquired immunodeficiency syndrome	8.47e-05	0.00114	CcSEcCtD
Crizotinib—TEK—blood—acquired immunodeficiency syndrome	8.47e-05	0.00132	CbGeAlD
Crizotinib—MAP3K3—blood—acquired immunodeficiency syndrome	8.47e-05	0.00132	CbGeAlD
Crizotinib—MAP4K5—blood—acquired immunodeficiency syndrome	8.47e-05	0.00132	CbGeAlD
Crizotinib—TYK2—lung—acquired immunodeficiency syndrome	8.47e-05	0.00132	CbGeAlD
Crizotinib—JAK2—spinal cord—acquired immunodeficiency syndrome	8.47e-05	0.00132	CbGeAlD
Crizotinib—ALK—brain—acquired immunodeficiency syndrome	8.46e-05	0.00132	CbGeAlD
Crizotinib—FER—brain—acquired immunodeficiency syndrome	8.46e-05	0.00132	CbGeAlD
Crizotinib—EPHA5—brain—acquired immunodeficiency syndrome	8.46e-05	0.00132	CbGeAlD
Crizotinib—TYRO3—brain—acquired immunodeficiency syndrome	8.46e-05	0.00132	CbGeAlD
Crizotinib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	8.42e-05	0.00113	CcSEcCtD
Crizotinib—LYN—brain—acquired immunodeficiency syndrome	8.42e-05	0.00131	CbGeAlD
Crizotinib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	8.41e-05	0.00113	CcSEcCtD
Crizotinib—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	8.41e-05	0.00113	CcSEcCtD
Crizotinib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	8.39e-05	0.00112	CcSEcCtD
Crizotinib—Nausea—Didanosine—acquired immunodeficiency syndrome	8.39e-05	0.00112	CcSEcCtD
Crizotinib—TNK1—brain—acquired immunodeficiency syndrome	8.37e-05	0.00131	CbGeAlD
Crizotinib—Syncope—Lamivudine—acquired immunodeficiency syndrome	8.36e-05	0.00112	CcSEcCtD
Crizotinib—IRAK1—lung—acquired immunodeficiency syndrome	8.36e-05	0.0013	CbGeAlD
Crizotinib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	8.35e-05	0.00112	CcSEcCtD
Crizotinib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	8.34e-05	0.00112	CcSEcCtD
Crizotinib—YES1—lymphoid tissue—acquired immunodeficiency syndrome	8.31e-05	0.0013	CbGeAlD
Crizotinib—BMPR1B—brain—acquired immunodeficiency syndrome	8.29e-05	0.00129	CbGeAlD
Crizotinib—MAP4K1—brain—acquired immunodeficiency syndrome	8.29e-05	0.00129	CbGeAlD
Crizotinib—MAP3K19—brain—acquired immunodeficiency syndrome	8.29e-05	0.00129	CbGeAlD
Crizotinib—Oedema—Ritonavir—acquired immunodeficiency syndrome	8.28e-05	0.00111	CcSEcCtD
Crizotinib—SLK—vagina—acquired immunodeficiency syndrome	8.26e-05	0.00129	CbGeAlD
Crizotinib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	8.26e-05	0.00111	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	8.26e-05	0.00111	CcSEcCtD
Crizotinib—PTK2B—central nervous system—acquired immunodeficiency syndrome	8.25e-05	0.00129	CbGeAlD
Crizotinib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	8.24e-05	0.0011	CcSEcCtD
Crizotinib—STK10—lymphoid tissue—acquired immunodeficiency syndrome	8.24e-05	0.00129	CbGeAlD
Crizotinib—EPHA4—nervous system—acquired immunodeficiency syndrome	8.22e-05	0.00128	CbGeAlD
Crizotinib—YES1—digestive system—acquired immunodeficiency syndrome	8.21e-05	0.00128	CbGeAlD
Crizotinib—TAOK3—lymphoid tissue—acquired immunodeficiency syndrome	8.2e-05	0.00128	CbGeAlD
Crizotinib—EPHB4—vagina—acquired immunodeficiency syndrome	8.2e-05	0.00128	CbGeAlD
Crizotinib—RPS6KB1—lung—acquired immunodeficiency syndrome	8.2e-05	0.00128	CbGeAlD
Crizotinib—MAP4K5—bone marrow—acquired immunodeficiency syndrome	8.19e-05	0.00128	CbGeAlD
Crizotinib—MAP3K3—bone marrow—acquired immunodeficiency syndrome	8.19e-05	0.00128	CbGeAlD
Crizotinib—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	8.19e-05	0.0011	CcSEcCtD
Crizotinib—ALK—lymph node—acquired immunodeficiency syndrome	8.18e-05	0.00128	CbGeAlD
Crizotinib—FER—lymph node—acquired immunodeficiency syndrome	8.18e-05	0.00128	CbGeAlD
Crizotinib—MAP4K5—spinal cord—acquired immunodeficiency syndrome	8.16e-05	0.00127	CbGeAlD
Crizotinib—MAP3K3—spinal cord—acquired immunodeficiency syndrome	8.16e-05	0.00127	CbGeAlD
Crizotinib—TEK—spinal cord—acquired immunodeficiency syndrome	8.16e-05	0.00127	CbGeAlD
Crizotinib—FGR—lung—acquired immunodeficiency syndrome	8.15e-05	0.00127	CbGeAlD
Crizotinib—LCK—lung—acquired immunodeficiency syndrome	8.15e-05	0.00127	CbGeAlD
Crizotinib—Shock—Ritonavir—acquired immunodeficiency syndrome	8.15e-05	0.00109	CcSEcCtD
Crizotinib—JAK2—vagina—acquired immunodeficiency syndrome	8.14e-05	0.00127	CbGeAlD
Crizotinib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	8.14e-05	0.00109	CcSEcCtD
Crizotinib—STK10—digestive system—acquired immunodeficiency syndrome	8.14e-05	0.00127	CbGeAlD
Crizotinib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	8.13e-05	0.00109	CcSEcCtD
Crizotinib—TNK2—brain—acquired immunodeficiency syndrome	8.13e-05	0.00127	CbGeAlD
Crizotinib—IGF1R—brain—acquired immunodeficiency syndrome	8.13e-05	0.00127	CbGeAlD
Crizotinib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	8.12e-05	0.00109	CcSEcCtD
Crizotinib—AXL—lung—acquired immunodeficiency syndrome	8.12e-05	0.00127	CbGeAlD
Crizotinib—Dizziness—Stavudine—acquired immunodeficiency syndrome	8.11e-05	0.00109	CcSEcCtD
Crizotinib—TAOK3—digestive system—acquired immunodeficiency syndrome	8.1e-05	0.00126	CbGeAlD
Crizotinib—EPHB6—blood—acquired immunodeficiency syndrome	8.09e-05	0.00126	CbGeAlD
Crizotinib—TNK1—lymph node—acquired immunodeficiency syndrome	8.09e-05	0.00126	CbGeAlD
Crizotinib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	8.08e-05	0.00108	CcSEcCtD
Crizotinib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	8.07e-05	0.00108	CcSEcCtD
Crizotinib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	8.07e-05	0.00108	CcSEcCtD
Crizotinib—MAP3K2—nervous system—acquired immunodeficiency syndrome	8.06e-05	0.00126	CbGeAlD
Crizotinib—EPHA2—vagina—acquired immunodeficiency syndrome	8.05e-05	0.00126	CbGeAlD
Crizotinib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	8.05e-05	0.00108	CcSEcCtD
Crizotinib—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	8.04e-05	0.00108	CcSEcCtD
Crizotinib—MAP4K2—brain—acquired immunodeficiency syndrome	8.02e-05	0.00125	CbGeAlD
Crizotinib—BMPR1B—lymph node—acquired immunodeficiency syndrome	8.01e-05	0.00125	CbGeAlD
Crizotinib—MAP4K1—lymph node—acquired immunodeficiency syndrome	8.01e-05	0.00125	CbGeAlD
Crizotinib—Constipation—Efavirenz—acquired immunodeficiency syndrome	8.01e-05	0.00107	CcSEcCtD
Crizotinib—Rash—Nevirapine—acquired immunodeficiency syndrome	8e-05	0.00107	CcSEcCtD
Crizotinib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	8e-05	0.00107	CcSEcCtD
Crizotinib—SRC—lymphoid tissue—acquired immunodeficiency syndrome	8e-05	0.00125	CbGeAlD
Crizotinib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	7.99e-05	0.00107	CcSEcCtD
Crizotinib—Dizziness—Abacavir—acquired immunodeficiency syndrome	7.99e-05	0.00107	CcSEcCtD
Crizotinib—ABL1—retina—acquired immunodeficiency syndrome	7.98e-05	0.00125	CbGeAlD
Crizotinib—Oedema—Saquinavir—acquired immunodeficiency syndrome	7.97e-05	0.00107	CcSEcCtD
Crizotinib—Infection—Saquinavir—acquired immunodeficiency syndrome	7.92e-05	0.00106	CcSEcCtD
Crizotinib—EPHA4—central nervous system—acquired immunodeficiency syndrome	7.91e-05	0.00123	CbGeAlD
Crizotinib—STK3—brain—acquired immunodeficiency syndrome	7.91e-05	0.00123	CbGeAlD
Crizotinib—TIE1—brain—acquired immunodeficiency syndrome	7.91e-05	0.00123	CbGeAlD
Crizotinib—SRC—digestive system—acquired immunodeficiency syndrome	7.9e-05	0.00123	CbGeAlD
Crizotinib—PTK2—nervous system—acquired immunodeficiency syndrome	7.89e-05	0.00123	CbGeAlD
Crizotinib—TBK1—nervous system—acquired immunodeficiency syndrome	7.89e-05	0.00123	CbGeAlD
Crizotinib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	7.88e-05	0.00106	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	7.88e-05	0.00106	CcSEcCtD
Crizotinib—TNK2—lymph node—acquired immunodeficiency syndrome	7.85e-05	0.00123	CbGeAlD
Crizotinib—IGF1R—lymph node—acquired immunodeficiency syndrome	7.85e-05	0.00123	CbGeAlD
Crizotinib—MAP3K3—vagina—acquired immunodeficiency syndrome	7.85e-05	0.00123	CbGeAlD
Crizotinib—MAP4K5—vagina—acquired immunodeficiency syndrome	7.85e-05	0.00123	CbGeAlD
Crizotinib—Shock—Saquinavir—acquired immunodeficiency syndrome	7.84e-05	0.00105	CcSEcCtD
Crizotinib—TYK2—nervous system—acquired immunodeficiency syndrome	7.84e-05	0.00122	CbGeAlD
Crizotinib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	7.83e-05	0.00105	CcSEcCtD
Crizotinib—YES1—blood—acquired immunodeficiency syndrome	7.82e-05	0.00122	CbGeAlD
Crizotinib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	7.82e-05	0.00105	CcSEcCtD
Crizotinib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	7.82e-05	0.00105	CcSEcCtD
Crizotinib—SLK—lung—acquired immunodeficiency syndrome	7.81e-05	0.00122	CbGeAlD
Crizotinib—EPHB6—spinal cord—acquired immunodeficiency syndrome	7.8e-05	0.00122	CbGeAlD
Crizotinib—Vomiting—Stavudine—acquired immunodeficiency syndrome	7.79e-05	0.00104	CcSEcCtD
Crizotinib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	7.79e-05	0.00104	CcSEcCtD
Crizotinib—MAP3K2—central nervous system—acquired immunodeficiency syndrome	7.76e-05	0.00121	CbGeAlD
Crizotinib—EPHB4—lung—acquired immunodeficiency syndrome	7.76e-05	0.00121	CbGeAlD
Crizotinib—Rash—Nelfinavir—acquired immunodeficiency syndrome	7.75e-05	0.00104	CcSEcCtD
Crizotinib—STK10—blood—acquired immunodeficiency syndrome	7.75e-05	0.00121	CbGeAlD
Crizotinib—MAP4K2—lymph node—acquired immunodeficiency syndrome	7.75e-05	0.00121	CbGeAlD
Crizotinib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	7.75e-05	0.00104	CcSEcCtD
Crizotinib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	7.74e-05	0.00104	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	7.73e-05	0.00104	CcSEcCtD
Crizotinib—Rash—Stavudine—acquired immunodeficiency syndrome	7.73e-05	0.00104	CcSEcCtD
Crizotinib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	7.72e-05	0.00103	CcSEcCtD
Crizotinib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	7.72e-05	0.00103	CcSEcCtD
Crizotinib—TAOK3—blood—acquired immunodeficiency syndrome	7.72e-05	0.0012	CbGeAlD
Crizotinib—AURKA—brain—acquired immunodeficiency syndrome	7.71e-05	0.0012	CbGeAlD
Crizotinib—JAK2—lung—acquired immunodeficiency syndrome	7.7e-05	0.0012	CbGeAlD
Crizotinib—Vomiting—Abacavir—acquired immunodeficiency syndrome	7.68e-05	0.00103	CcSEcCtD
Crizotinib—Constipation—Delavirdine—acquired immunodeficiency syndrome	7.66e-05	0.00103	CcSEcCtD
Crizotinib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	7.64e-05	0.00102	CcSEcCtD
Crizotinib—TESK1—brain—acquired immunodeficiency syndrome	7.64e-05	0.00119	CbGeAlD
Crizotinib—STK3—lymph node—acquired immunodeficiency syndrome	7.64e-05	0.00119	CbGeAlD
Crizotinib—TIE1—lymph node—acquired immunodeficiency syndrome	7.64e-05	0.00119	CbGeAlD
Crizotinib—Rash—Abacavir—acquired immunodeficiency syndrome	7.61e-05	0.00102	CcSEcCtD
Crizotinib—EPHA2—lung—acquired immunodeficiency syndrome	7.61e-05	0.00119	CbGeAlD
Crizotinib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	7.61e-05	0.00102	CcSEcCtD
Crizotinib—Oedema—Lamivudine—acquired immunodeficiency syndrome	7.61e-05	0.00102	CcSEcCtD
Crizotinib—PTK2—central nervous system—acquired immunodeficiency syndrome	7.6e-05	0.00119	CbGeAlD
Crizotinib—TBK1—central nervous system—acquired immunodeficiency syndrome	7.6e-05	0.00119	CbGeAlD
Crizotinib—RPS6KB1—nervous system—acquired immunodeficiency syndrome	7.59e-05	0.00119	CbGeAlD
Crizotinib—YES1—bone marrow—acquired immunodeficiency syndrome	7.57e-05	0.00118	CbGeAlD
Crizotinib—Infection—Lamivudine—acquired immunodeficiency syndrome	7.56e-05	0.00101	CcSEcCtD
Crizotinib—TYK2—central nervous system—acquired immunodeficiency syndrome	7.55e-05	0.00118	CbGeAlD
Crizotinib—FGR—nervous system—acquired immunodeficiency syndrome	7.55e-05	0.00118	CbGeAlD
Crizotinib—Nausea—Nevirapine—acquired immunodeficiency syndrome	7.54e-05	0.00101	CcSEcCtD
Crizotinib—YES1—spinal cord—acquired immunodeficiency syndrome	7.54e-05	0.00118	CbGeAlD
Crizotinib—SRC—blood—acquired immunodeficiency syndrome	7.52e-05	0.00117	CbGeAlD
Crizotinib—AXL—nervous system—acquired immunodeficiency syndrome	7.52e-05	0.00117	CbGeAlD
Crizotinib—EPHB6—vagina—acquired immunodeficiency syndrome	7.5e-05	0.00117	CbGeAlD
Crizotinib—STK10—bone marrow—acquired immunodeficiency syndrome	7.5e-05	0.00117	CbGeAlD
Crizotinib—Shock—Lamivudine—acquired immunodeficiency syndrome	7.48e-05	0.001	CcSEcCtD
Crizotinib—TAOK3—bone marrow—acquired immunodeficiency syndrome	7.47e-05	0.00117	CbGeAlD
Crizotinib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	7.46e-05	0.000999	CcSEcCtD
Crizotinib—AURKA—lymph node—acquired immunodeficiency syndrome	7.45e-05	0.00116	CbGeAlD
Crizotinib—TAOK3—spinal cord—acquired immunodeficiency syndrome	7.44e-05	0.00116	CbGeAlD
Crizotinib—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	7.44e-05	0.000997	CcSEcCtD
Crizotinib—MERTK—brain—acquired immunodeficiency syndrome	7.43e-05	0.00116	CbGeAlD
Crizotinib—TEK—lung—acquired immunodeficiency syndrome	7.42e-05	0.00116	CbGeAlD
Crizotinib—MAP4K5—lung—acquired immunodeficiency syndrome	7.42e-05	0.00116	CbGeAlD
Crizotinib—MAP3K3—lung—acquired immunodeficiency syndrome	7.42e-05	0.00116	CbGeAlD
Crizotinib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	7.4e-05	0.000992	CcSEcCtD
Crizotinib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	7.39e-05	0.00099	CcSEcCtD
Crizotinib—TESK1—lymph node—acquired immunodeficiency syndrome	7.39e-05	0.00115	CbGeAlD
Crizotinib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	7.38e-05	0.000989	CcSEcCtD
Crizotinib—RPS6KB1—central nervous system—acquired immunodeficiency syndrome	7.31e-05	0.00114	CbGeAlD
Crizotinib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	7.3e-05	0.000979	CcSEcCtD
Crizotinib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	7.29e-05	0.000977	CcSEcCtD
Crizotinib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	7.29e-05	0.000977	CcSEcCtD
Crizotinib—Nausea—Stavudine—acquired immunodeficiency syndrome	7.28e-05	0.000976	CcSEcCtD
Crizotinib—LIMK2—brain—acquired immunodeficiency syndrome	7.27e-05	0.00113	CbGeAlD
Crizotinib—FGR—central nervous system—acquired immunodeficiency syndrome	7.27e-05	0.00113	CbGeAlD
Crizotinib—YES1—vagina—acquired immunodeficiency syndrome	7.25e-05	0.00113	CbGeAlD
Crizotinib—SRC—spinal cord—acquired immunodeficiency syndrome	7.25e-05	0.00113	CbGeAlD
Crizotinib—NUAK2—brain—acquired immunodeficiency syndrome	7.25e-05	0.00113	CbGeAlD
Crizotinib—AXL—central nervous system—acquired immunodeficiency syndrome	7.24e-05	0.00113	CbGeAlD
Crizotinib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	7.2e-05	0.000965	CcSEcCtD
Crizotinib—MAP3K12—brain—acquired immunodeficiency syndrome	7.19e-05	0.00112	CbGeAlD
Crizotinib—ACVR1—brain—acquired immunodeficiency syndrome	7.19e-05	0.00112	CbGeAlD
Crizotinib—STK10—vagina—acquired immunodeficiency syndrome	7.18e-05	0.00112	CbGeAlD
Crizotinib—MERTK—lymph node—acquired immunodeficiency syndrome	7.18e-05	0.00112	CbGeAlD
Crizotinib—CSF1R—lymphoid tissue—acquired immunodeficiency syndrome	7.18e-05	0.00112	CbGeAlD
Crizotinib—Nausea—Abacavir—acquired immunodeficiency syndrome	7.17e-05	0.000961	CcSEcCtD
Crizotinib—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	7.16e-05	0.000959	CcSEcCtD
Crizotinib—TAOK3—vagina—acquired immunodeficiency syndrome	7.16e-05	0.00112	CbGeAlD
Crizotinib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	7.15e-05	0.000958	CcSEcCtD
Crizotinib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	7.14e-05	0.000957	CcSEcCtD
Crizotinib—JAK2—nervous system—acquired immunodeficiency syndrome	7.13e-05	0.00111	CbGeAlD
Crizotinib—Asthenia—Indinavir—acquired immunodeficiency syndrome	7.11e-05	0.000952	CcSEcCtD
Crizotinib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	7.11e-05	0.000952	CcSEcCtD
Crizotinib—EPHB6—lung—acquired immunodeficiency syndrome	7.1e-05	0.00111	CbGeAlD
Crizotinib—CSF1R—digestive system—acquired immunodeficiency syndrome	7.09e-05	0.00111	CbGeAlD
Crizotinib—Constipation—Ritonavir—acquired immunodeficiency syndrome	7.08e-05	0.000949	CcSEcCtD
Crizotinib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	7.08e-05	0.000949	CcSEcCtD
Crizotinib—STK35—brain—acquired immunodeficiency syndrome	7.05e-05	0.0011	CbGeAlD
Crizotinib—EPHA2—nervous system—acquired immunodeficiency syndrome	7.05e-05	0.0011	CbGeAlD
Crizotinib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	7.05e-05	0.000944	CcSEcCtD
Crizotinib—LIMK2—lymph node—acquired immunodeficiency syndrome	7.03e-05	0.0011	CbGeAlD
Crizotinib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	7.02e-05	0.00094	CcSEcCtD
Crizotinib—ABL1—skin of body—acquired immunodeficiency syndrome	7.01e-05	0.00109	CbGeAlD
Crizotinib—NUAK2—lymph node—acquired immunodeficiency syndrome	7e-05	0.00109	CbGeAlD
Crizotinib—MAP3K12—lymph node—acquired immunodeficiency syndrome	6.95e-05	0.00108	CbGeAlD
Crizotinib—FLT3—lymph node—acquired immunodeficiency syndrome	6.95e-05	0.00108	CbGeAlD
Crizotinib—ACVR1—lymph node—acquired immunodeficiency syndrome	6.95e-05	0.00108	CbGeAlD
Crizotinib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	6.93e-05	0.000929	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	6.88e-05	0.000922	CcSEcCtD
Crizotinib—TEK—nervous system—acquired immunodeficiency syndrome	6.88e-05	0.00107	CbGeAlD
Crizotinib—MAP3K3—nervous system—acquired immunodeficiency syndrome	6.88e-05	0.00107	CbGeAlD
Crizotinib—MAP4K5—nervous system—acquired immunodeficiency syndrome	6.88e-05	0.00107	CbGeAlD
Crizotinib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	6.87e-05	0.000921	CcSEcCtD
Crizotinib—ABL2—brain—acquired immunodeficiency syndrome	6.87e-05	0.00107	CbGeAlD
Crizotinib—JAK2—central nervous system—acquired immunodeficiency syndrome	6.87e-05	0.00107	CbGeAlD
Crizotinib—YES1—lung—acquired immunodeficiency syndrome	6.86e-05	0.00107	CbGeAlD
Crizotinib—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	6.83e-05	0.000915	CcSEcCtD
Crizotinib—Constipation—Saquinavir—acquired immunodeficiency syndrome	6.82e-05	0.000913	CcSEcCtD
Crizotinib—STK35—lymph node—acquired immunodeficiency syndrome	6.81e-05	0.00106	CbGeAlD
Crizotinib—STK10—lung—acquired immunodeficiency syndrome	6.79e-05	0.00106	CbGeAlD
Crizotinib—EPHA2—central nervous system—acquired immunodeficiency syndrome	6.79e-05	0.00106	CbGeAlD
Crizotinib—BMP2K—brain—acquired immunodeficiency syndrome	6.78e-05	0.00106	CbGeAlD
Crizotinib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	6.78e-05	0.000908	CcSEcCtD
Crizotinib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	6.78e-05	0.000908	CcSEcCtD
Crizotinib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	6.77e-05	0.000908	CcSEcCtD
Crizotinib—TAOK3—lung—acquired immunodeficiency syndrome	6.77e-05	0.00106	CbGeAlD
Crizotinib—CSF1R—blood—acquired immunodeficiency syndrome	6.75e-05	0.00105	CbGeAlD
Crizotinib—Rash—Zidovudine—acquired immunodeficiency syndrome	6.72e-05	0.0009	CcSEcCtD
Crizotinib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	6.72e-05	0.0009	CcSEcCtD
Crizotinib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	6.71e-05	0.000899	CcSEcCtD
Crizotinib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	6.69e-05	0.000897	CcSEcCtD
Crizotinib—ABL2—lymph node—acquired immunodeficiency syndrome	6.64e-05	0.00104	CbGeAlD
Crizotinib—MAP3K3—central nervous system—acquired immunodeficiency syndrome	6.62e-05	0.00103	CbGeAlD
Crizotinib—TEK—central nervous system—acquired immunodeficiency syndrome	6.62e-05	0.00103	CbGeAlD
Crizotinib—MAP4K5—central nervous system—acquired immunodeficiency syndrome	6.62e-05	0.00103	CbGeAlD
Crizotinib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	6.61e-05	0.000886	CcSEcCtD
Crizotinib—SRC—lung—acquired immunodeficiency syndrome	6.6e-05	0.00103	CbGeAlD
Crizotinib—EPHB6—nervous system—acquired immunodeficiency syndrome	6.57e-05	0.00103	CbGeAlD
Crizotinib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	6.57e-05	0.00088	CcSEcCtD
Crizotinib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	6.56e-05	0.000879	CcSEcCtD
Crizotinib—BMP2K—lymph node—acquired immunodeficiency syndrome	6.56e-05	0.00102	CbGeAlD
Crizotinib—PTK2B—brain—acquired immunodeficiency syndrome	6.55e-05	0.00102	CbGeAlD
Crizotinib—Dizziness—Indinavir—acquired immunodeficiency syndrome	6.55e-05	0.000878	CcSEcCtD
Crizotinib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	6.55e-05	0.000877	CcSEcCtD
Crizotinib—CSF1R—bone marrow—acquired immunodeficiency syndrome	6.54e-05	0.00102	CbGeAlD
Crizotinib—CSF1R—spinal cord—acquired immunodeficiency syndrome	6.51e-05	0.00102	CbGeAlD
Crizotinib—Constipation—Lamivudine—acquired immunodeficiency syndrome	6.5e-05	0.000871	CcSEcCtD
Crizotinib—RIPK2—brain—acquired immunodeficiency syndrome	6.5e-05	0.00101	CbGeAlD
Crizotinib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	6.43e-05	0.000861	CcSEcCtD
Crizotinib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	6.41e-05	0.000858	CcSEcCtD
Crizotinib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	6.4e-05	0.000999	CbGeAlD
Crizotinib—YES1—nervous system—acquired immunodeficiency syndrome	6.35e-05	0.000991	CbGeAlD
Crizotinib—PTK2B—lymph node—acquired immunodeficiency syndrome	6.33e-05	0.000988	CbGeAlD
Crizotinib—Nausea—Zidovudine—acquired immunodeficiency syndrome	6.33e-05	0.000848	CcSEcCtD
Crizotinib—EPHB6—central nervous system—acquired immunodeficiency syndrome	6.33e-05	0.000987	CbGeAlD
Crizotinib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	6.3e-05	0.000844	CcSEcCtD
Crizotinib—Vomiting—Indinavir—acquired immunodeficiency syndrome	6.3e-05	0.000844	CcSEcCtD
Crizotinib—STK10—nervous system—acquired immunodeficiency syndrome	6.29e-05	0.000982	CbGeAlD
Crizotinib—EPHA4—brain—acquired immunodeficiency syndrome	6.28e-05	0.00098	CbGeAlD
Crizotinib—RIPK2—lymph node—acquired immunodeficiency syndrome	6.28e-05	0.00098	CbGeAlD
Crizotinib—TAOK3—nervous system—acquired immunodeficiency syndrome	6.27e-05	0.000978	CbGeAlD
Crizotinib—CSF1R—vagina—acquired immunodeficiency syndrome	6.26e-05	0.000977	CbGeAlD
Crizotinib—Rash—Indinavir—acquired immunodeficiency syndrome	6.25e-05	0.000837	CcSEcCtD
Crizotinib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	6.24e-05	0.000836	CcSEcCtD
Crizotinib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	6.19e-05	0.000829	CcSEcCtD
Crizotinib—MAP3K2—brain—acquired immunodeficiency syndrome	6.16e-05	0.000961	CbGeAlD
Crizotinib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	6.13e-05	0.000821	CcSEcCtD
Crizotinib—YES1—central nervous system—acquired immunodeficiency syndrome	6.11e-05	0.000954	CbGeAlD
Crizotinib—SRC—nervous system—acquired immunodeficiency syndrome	6.11e-05	0.000953	CbGeAlD
Crizotinib—EPHA4—lymph node—acquired immunodeficiency syndrome	6.07e-05	0.000947	CbGeAlD
Crizotinib—STK10—central nervous system—acquired immunodeficiency syndrome	6.06e-05	0.000945	CbGeAlD
Crizotinib—TAOK3—central nervous system—acquired immunodeficiency syndrome	6.03e-05	0.000942	CbGeAlD
Crizotinib—TBK1—brain—acquired immunodeficiency syndrome	6.03e-05	0.000942	CbGeAlD
Crizotinib—PTK2—brain—acquired immunodeficiency syndrome	6.03e-05	0.000942	CbGeAlD
Crizotinib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	6.01e-05	0.000806	CcSEcCtD
Crizotinib—TYK2—brain—acquired immunodeficiency syndrome	5.99e-05	0.000935	CbGeAlD
Crizotinib—MAP3K2—lymph node—acquired immunodeficiency syndrome	5.95e-05	0.000929	CbGeAlD
Crizotinib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	5.95e-05	0.000798	CcSEcCtD
Crizotinib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	5.94e-05	0.000796	CcSEcCtD
Crizotinib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	5.92e-05	0.000794	CcSEcCtD
Crizotinib—CSF1R—lung—acquired immunodeficiency syndrome	5.92e-05	0.000924	CbGeAlD
Crizotinib—IRAK1—brain—acquired immunodeficiency syndrome	5.91e-05	0.000923	CbGeAlD
Crizotinib—Rash—Efavirenz—acquired immunodeficiency syndrome	5.9e-05	0.000791	CcSEcCtD
Crizotinib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	5.9e-05	0.00079	CcSEcCtD
Crizotinib—Nausea—Indinavir—acquired immunodeficiency syndrome	5.89e-05	0.000789	CcSEcCtD
Crizotinib—SRC—central nervous system—acquired immunodeficiency syndrome	5.88e-05	0.000918	CbGeAlD
Crizotinib—PTK2—lymph node—acquired immunodeficiency syndrome	5.83e-05	0.00091	CbGeAlD
Crizotinib—TBK1—lymph node—acquired immunodeficiency syndrome	5.83e-05	0.00091	CbGeAlD
Crizotinib—RPS6KB1—brain—acquired immunodeficiency syndrome	5.8e-05	0.000906	CbGeAlD
Crizotinib—TYK2—lymph node—acquired immunodeficiency syndrome	5.79e-05	0.000904	CbGeAlD
Crizotinib—FGR—brain—acquired immunodeficiency syndrome	5.77e-05	0.0009	CbGeAlD
Crizotinib—AXL—brain—acquired immunodeficiency syndrome	5.75e-05	0.000897	CbGeAlD
Crizotinib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	5.72e-05	0.000766	CcSEcCtD
Crizotinib—IRAK1—lymph node—acquired immunodeficiency syndrome	5.72e-05	0.000892	CbGeAlD
Crizotinib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	5.69e-05	0.000763	CcSEcCtD
Crizotinib—ABL1—lymphoid tissue—acquired immunodeficiency syndrome	5.67e-05	0.000886	CbGeAlD
Crizotinib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	5.67e-05	0.000759	CcSEcCtD
Crizotinib—Rash—Delavirdine—acquired immunodeficiency syndrome	5.65e-05	0.000757	CcSEcCtD
Crizotinib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	5.64e-05	0.000756	CcSEcCtD
Crizotinib—RPS6KB1—lymph node—acquired immunodeficiency syndrome	5.61e-05	0.000875	CbGeAlD
Crizotinib—ABL1—digestive system—acquired immunodeficiency syndrome	5.6e-05	0.000875	CbGeAlD
Crizotinib—FGR—lymph node—acquired immunodeficiency syndrome	5.57e-05	0.00087	CbGeAlD
Crizotinib—LCK—lymph node—acquired immunodeficiency syndrome	5.57e-05	0.00087	CbGeAlD
Crizotinib—Nausea—Efavirenz—acquired immunodeficiency syndrome	5.56e-05	0.000745	CcSEcCtD
Crizotinib—AXL—lymph node—acquired immunodeficiency syndrome	5.55e-05	0.000866	CbGeAlD
Crizotinib—SLK—brain—acquired immunodeficiency syndrome	5.53e-05	0.000863	CbGeAlD
Crizotinib—EPHB4—brain—acquired immunodeficiency syndrome	5.49e-05	0.000857	CbGeAlD
Crizotinib—CSF1R—nervous system—acquired immunodeficiency syndrome	5.48e-05	0.000856	CbGeAlD
Crizotinib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	5.48e-05	0.000734	CcSEcCtD
Crizotinib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	5.46e-05	0.000731	CcSEcCtD
Crizotinib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	5.45e-05	0.000731	CcSEcCtD
Crizotinib—JAK2—brain—acquired immunodeficiency syndrome	5.45e-05	0.000851	CbGeAlD
Crizotinib—EPHA2—brain—acquired immunodeficiency syndrome	5.39e-05	0.000841	CbGeAlD
Crizotinib—SLK—lymph node—acquired immunodeficiency syndrome	5.34e-05	0.000834	CbGeAlD
Crizotinib—ABL1—blood—acquired immunodeficiency syndrome	5.34e-05	0.000833	CbGeAlD
Crizotinib—Nausea—Delavirdine—acquired immunodeficiency syndrome	5.32e-05	0.000713	CcSEcCtD
Crizotinib—EPHB4—lymph node—acquired immunodeficiency syndrome	5.31e-05	0.000828	CbGeAlD
Crizotinib—CSF1R—central nervous system—acquired immunodeficiency syndrome	5.28e-05	0.000824	CbGeAlD
Crizotinib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	5.27e-05	0.000706	CcSEcCtD
Crizotinib—JAK2—lymph node—acquired immunodeficiency syndrome	5.27e-05	0.000822	CbGeAlD
Crizotinib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	5.27e-05	0.000706	CcSEcCtD
Crizotinib—TEK—brain—acquired immunodeficiency syndrome	5.26e-05	0.00082	CbGeAlD
Crizotinib—MAP3K3—brain—acquired immunodeficiency syndrome	5.26e-05	0.00082	CbGeAlD
Crizotinib—MAP4K5—brain—acquired immunodeficiency syndrome	5.26e-05	0.00082	CbGeAlD
Crizotinib—Rash—Ritonavir—acquired immunodeficiency syndrome	5.22e-05	0.0007	CcSEcCtD
Crizotinib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	5.22e-05	0.000699	CcSEcCtD
Crizotinib—EPHA2—lymph node—acquired immunodeficiency syndrome	5.2e-05	0.000812	CbGeAlD
Crizotinib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	5.2e-05	0.000697	CcSEcCtD
Crizotinib—ABL1—bone marrow—acquired immunodeficiency syndrome	5.17e-05	0.000806	CbGeAlD
Crizotinib—ABL1—spinal cord—acquired immunodeficiency syndrome	5.14e-05	0.000803	CbGeAlD
Crizotinib—TEK—lymph node—acquired immunodeficiency syndrome	5.08e-05	0.000792	CbGeAlD
Crizotinib—MAP4K5—lymph node—acquired immunodeficiency syndrome	5.08e-05	0.000792	CbGeAlD
Crizotinib—MAP3K3—lymph node—acquired immunodeficiency syndrome	5.08e-05	0.000792	CbGeAlD
Crizotinib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	5.07e-05	0.000679	CcSEcCtD
Crizotinib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	5.03e-05	0.000674	CcSEcCtD
Crizotinib—Rash—Saquinavir—acquired immunodeficiency syndrome	5.03e-05	0.000674	CcSEcCtD
Crizotinib—EPHB6—brain—acquired immunodeficiency syndrome	5.02e-05	0.000784	CbGeAlD
Crizotinib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	5.02e-05	0.000673	CcSEcCtD
Crizotinib—ABL1—vagina—acquired immunodeficiency syndrome	4.95e-05	0.000772	CbGeAlD
Crizotinib—Nausea—Ritonavir—acquired immunodeficiency syndrome	4.92e-05	0.000659	CcSEcCtD
Crizotinib—YES1—brain—acquired immunodeficiency syndrome	4.85e-05	0.000757	CbGeAlD
Crizotinib—EPHB6—lymph node—acquired immunodeficiency syndrome	4.85e-05	0.000757	CbGeAlD
Crizotinib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	4.84e-05	0.000648	CcSEcCtD
Crizotinib—STK10—brain—acquired immunodeficiency syndrome	4.81e-05	0.000751	CbGeAlD
Crizotinib—Rash—Lamivudine—acquired immunodeficiency syndrome	4.8e-05	0.000643	CcSEcCtD
Crizotinib—TAOK3—brain—acquired immunodeficiency syndrome	4.79e-05	0.000748	CbGeAlD
Crizotinib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	4.79e-05	0.000642	CcSEcCtD
Crizotinib—Nausea—Saquinavir—acquired immunodeficiency syndrome	4.74e-05	0.000634	CcSEcCtD
Crizotinib—YES1—lymph node—acquired immunodeficiency syndrome	4.69e-05	0.000732	CbGeAlD
Crizotinib—ABL1—lung—acquired immunodeficiency syndrome	4.68e-05	0.000731	CbGeAlD
Crizotinib—SRC—brain—acquired immunodeficiency syndrome	4.67e-05	0.000729	CbGeAlD
Crizotinib—STK10—lymph node—acquired immunodeficiency syndrome	4.65e-05	0.000725	CbGeAlD
Crizotinib—TAOK3—lymph node—acquired immunodeficiency syndrome	4.63e-05	0.000722	CbGeAlD
Crizotinib—ABCB1—blood plasma—acquired immunodeficiency syndrome	4.53e-05	0.000707	CbGeAlD
Crizotinib—Nausea—Lamivudine—acquired immunodeficiency syndrome	4.52e-05	0.000605	CcSEcCtD
Crizotinib—SRC—lymph node—acquired immunodeficiency syndrome	4.51e-05	0.000704	CbGeAlD
Crizotinib—ABL1—nervous system—acquired immunodeficiency syndrome	4.33e-05	0.000677	CbGeAlD
Crizotinib—CSF1R—brain—acquired immunodeficiency syndrome	4.19e-05	0.000654	CbGeAlD
Crizotinib—ABL1—central nervous system—acquired immunodeficiency syndrome	4.17e-05	0.000651	CbGeAlD
Crizotinib—CSF1R—lymph node—acquired immunodeficiency syndrome	4.05e-05	0.000632	CbGeAlD
Crizotinib—ABL1—brain—acquired immunodeficiency syndrome	3.31e-05	0.000517	CbGeAlD
Crizotinib—CYP3A5—digestive system—acquired immunodeficiency syndrome	3.28e-05	0.000512	CbGeAlD
Crizotinib—ABL1—lymph node—acquired immunodeficiency syndrome	3.2e-05	0.0005	CbGeAlD
Crizotinib—CYP3A5—blood—acquired immunodeficiency syndrome	3.13e-05	0.000488	CbGeAlD
Crizotinib—CYP3A5—vagina—acquired immunodeficiency syndrome	2.9e-05	0.000452	CbGeAlD
Crizotinib—CYP3A5—lung—acquired immunodeficiency syndrome	2.74e-05	0.000428	CbGeAlD
Crizotinib—ABCB1—retina—acquired immunodeficiency syndrome	2.48e-05	0.000387	CbGeAlD
Crizotinib—CYP3A4—digestive system—acquired immunodeficiency syndrome	2.46e-05	0.000384	CbGeAlD
Crizotinib—CYP3A4—blood—acquired immunodeficiency syndrome	2.35e-05	0.000366	CbGeAlD
Crizotinib—CYP3A4—nervous system—acquired immunodeficiency syndrome	1.9e-05	0.000297	CbGeAlD
Crizotinib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	1.83e-05	0.000286	CbGeAlD
Crizotinib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	1.76e-05	0.000275	CbGeAlD
Crizotinib—ABCB1—digestive system—acquired immunodeficiency syndrome	1.74e-05	0.000272	CbGeAlD
Crizotinib—ABCB1—blood—acquired immunodeficiency syndrome	1.66e-05	0.000259	CbGeAlD
Crizotinib—ABCB1—bone marrow—acquired immunodeficiency syndrome	1.61e-05	0.000251	CbGeAlD
Crizotinib—ABCB1—spinal cord—acquired immunodeficiency syndrome	1.6e-05	0.00025	CbGeAlD
Crizotinib—ABCB1—vagina—acquired immunodeficiency syndrome	1.54e-05	0.00024	CbGeAlD
Crizotinib—ABCB1—lung—acquired immunodeficiency syndrome	1.46e-05	0.000227	CbGeAlD
Crizotinib—ABCB1—nervous system—acquired immunodeficiency syndrome	1.35e-05	0.00021	CbGeAlD
Crizotinib—ABCB1—central nervous system—acquired immunodeficiency syndrome	1.3e-05	0.000203	CbGeAlD
Crizotinib—ABCB1—brain—acquired immunodeficiency syndrome	1.03e-05	0.000161	CbGeAlD
Crizotinib—ABCB1—lymph node—acquired immunodeficiency syndrome	9.96e-06	0.000155	CbGeAlD
Crizotinib—JAK3—Immune System—IL2—acquired immunodeficiency syndrome	4.43e-06	8.6e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.42e-06	8.58e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.42e-06	8.58e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.42e-06	8.57e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—ALB—acquired immunodeficiency syndrome	4.39e-06	8.53e-05	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—TNF—acquired immunodeficiency syndrome	4.39e-06	8.52e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD79A—acquired immunodeficiency syndrome	4.39e-06	8.51e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.38e-06	8.5e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IFNG—acquired immunodeficiency syndrome	4.38e-06	8.5e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.38e-06	8.49e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD40LG—acquired immunodeficiency syndrome	4.36e-06	8.47e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.36e-06	8.45e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CXCR4—acquired immunodeficiency syndrome	4.36e-06	8.45e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—IL2—acquired immunodeficiency syndrome	4.35e-06	8.44e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD40LG—acquired immunodeficiency syndrome	4.34e-06	8.43e-05	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—TNF—acquired immunodeficiency syndrome	4.33e-06	8.4e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—IL2—acquired immunodeficiency syndrome	4.33e-06	8.4e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD8A—acquired immunodeficiency syndrome	4.31e-06	8.37e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CSF2—acquired immunodeficiency syndrome	4.31e-06	8.37e-05	CbGpPWpGaD
Crizotinib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	4.3e-06	8.34e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	4.3e-06	8.34e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD8A—acquired immunodeficiency syndrome	4.29e-06	8.33e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CSF2—acquired immunodeficiency syndrome	4.29e-06	8.33e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—CD4—acquired immunodeficiency syndrome	4.29e-06	8.33e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—IFNG—acquired immunodeficiency syndrome	4.28e-06	8.3e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—IFNG—acquired immunodeficiency syndrome	4.26e-06	8.27e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	4.26e-06	8.26e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—CD4—acquired immunodeficiency syndrome	4.25e-06	8.25e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—CD4—acquired immunodeficiency syndrome	4.23e-06	8.22e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—CD4—acquired immunodeficiency syndrome	4.23e-06	8.21e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	4.22e-06	8.19e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	4.2e-06	8.15e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.17e-06	8.09e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—CD4—acquired immunodeficiency syndrome	4.16e-06	8.06e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—HLA-B—acquired immunodeficiency syndrome	4.15e-06	8.05e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HLA-B—acquired immunodeficiency syndrome	4.13e-06	8.01e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—CD4—acquired immunodeficiency syndrome	4.13e-06	8.01e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—CD4—acquired immunodeficiency syndrome	4.12e-06	7.99e-05	CbGpPWpGaD
Crizotinib—LYN—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	4.1e-06	7.96e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.1e-06	7.95e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	4.08e-06	7.93e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD40LG—acquired immunodeficiency syndrome	4.08e-06	7.92e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—IL2—acquired immunodeficiency syndrome	4.07e-06	7.89e-05	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.06e-06	7.87e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.04e-06	7.85e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.04e-06	7.84e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD8A—acquired immunodeficiency syndrome	4.04e-06	7.83e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CSF2—acquired immunodeficiency syndrome	4.04e-06	7.83e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IFNA1—acquired immunodeficiency syndrome	4e-06	7.76e-05	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.99e-06	7.74e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.99e-06	7.73e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—CD4—acquired immunodeficiency syndrome	3.98e-06	7.72e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.96e-06	7.69e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.96e-06	7.68e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL2—acquired immunodeficiency syndrome	3.95e-06	7.67e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL2—acquired immunodeficiency syndrome	3.89e-06	7.55e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—ALB—acquired immunodeficiency syndrome	3.89e-06	7.55e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HLA-B—acquired immunodeficiency syndrome	3.88e-06	7.54e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD79A—acquired immunodeficiency syndrome	3.88e-06	7.54e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.88e-06	7.53e-05	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—IL6—acquired immunodeficiency syndrome	3.88e-06	7.52e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.86e-06	7.49e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CXCR4—acquired immunodeficiency syndrome	3.86e-06	7.48e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.85e-06	7.47e-05	CbGpPWpGaD
Crizotinib—JAK2—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	3.84e-06	7.45e-05	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.82e-06	7.42e-05	CbGpPWpGaD
Crizotinib—SRC—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	3.8e-06	7.38e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL2—acquired immunodeficiency syndrome	3.8e-06	7.37e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.8e-06	7.37e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.79e-06	7.36e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL2—acquired immunodeficiency syndrome	3.79e-06	7.35e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	3.77e-06	7.32e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.74e-06	7.26e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.72e-06	7.22e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.72e-06	7.22e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.7e-06	7.19e-05	CbGpPWpGaD
Crizotinib—LYN—Axon guidance—IL6—acquired immunodeficiency syndrome	3.65e-06	7.08e-05	CbGpPWpGaD
Crizotinib—ABL1—Axon guidance—IL6—acquired immunodeficiency syndrome	3.63e-06	7.05e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.6e-06	6.99e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.59e-06	6.96e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD40LG—acquired immunodeficiency syndrome	3.58e-06	6.94e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—IL2—acquired immunodeficiency syndrome	3.56e-06	6.91e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.55e-06	6.88e-05	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—IL6—acquired immunodeficiency syndrome	3.54e-06	6.87e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CSF2—acquired immunodeficiency syndrome	3.54e-06	6.86e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD8A—acquired immunodeficiency syndrome	3.54e-06	6.86e-05	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—IL6—acquired immunodeficiency syndrome	3.53e-06	6.84e-05	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—IL6—acquired immunodeficiency syndrome	3.53e-06	6.84e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.5e-06	6.78e-05	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—IL6—acquired immunodeficiency syndrome	3.49e-06	6.78e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IFNG—acquired immunodeficiency syndrome	3.49e-06	6.77e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—CD4—acquired immunodeficiency syndrome	3.49e-06	6.77e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.48e-06	6.76e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.48e-06	6.76e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.47e-06	6.73e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.44e-06	6.68e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IFNG—acquired immunodeficiency syndrome	3.44e-06	6.68e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.42e-06	6.64e-05	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—IL6—acquired immunodeficiency syndrome	3.42e-06	6.63e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CCR5—acquired immunodeficiency syndrome	3.41e-06	6.61e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-B—acquired immunodeficiency syndrome	3.4e-06	6.6e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.4e-06	6.6e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.4e-06	6.6e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—CD4—acquired immunodeficiency syndrome	3.37e-06	6.54e-05	CbGpPWpGaD
Crizotinib—LCK—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	3.36e-06	6.52e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	3.35e-06	6.5e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—CD4—acquired immunodeficiency syndrome	3.32e-06	6.45e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling by NGF—IL6—acquired immunodeficiency syndrome	3.31e-06	6.42e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	3.3e-06	6.4e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IFNG—acquired immunodeficiency syndrome	3.26e-06	6.33e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.24e-06	6.3e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.24e-06	6.3e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.23e-06	6.26e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.22e-06	6.25e-05	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—IL6—acquired immunodeficiency syndrome	3.22e-06	6.24e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.21e-06	6.23e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.18e-06	6.16e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IFNG—acquired immunodeficiency syndrome	3.17e-06	6.15e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD40LG—acquired immunodeficiency syndrome	3.17e-06	6.14e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—IL2—acquired immunodeficiency syndrome	3.15e-06	6.12e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—CD4—acquired immunodeficiency syndrome	3.15e-06	6.12e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.15e-06	6.11e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD8A—acquired immunodeficiency syndrome	3.13e-06	6.07e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CSF2—acquired immunodeficiency syndrome	3.13e-06	6.07e-05	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.13e-06	6.07e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL2—acquired immunodeficiency syndrome	3.1e-06	6.02e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—CD4—acquired immunodeficiency syndrome	3.09e-06	5.99e-05	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.08e-06	5.99e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.08e-06	5.98e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—CD4—acquired immunodeficiency syndrome	3.06e-06	5.94e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL2—acquired immunodeficiency syndrome	3.06e-06	5.93e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.05e-06	5.92e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.05e-06	5.92e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.02e-06	5.86e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-B—acquired immunodeficiency syndrome	3.01e-06	5.84e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CCR5—acquired immunodeficiency syndrome	2.99e-06	5.79e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.96e-06	5.75e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	2.96e-06	5.75e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.95e-06	5.72e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.93e-06	5.68e-05	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.93e-06	5.68e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL2—acquired immunodeficiency syndrome	2.9e-06	5.63e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—IL6—acquired immunodeficiency syndrome	2.88e-06	5.59e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.87e-06	5.57e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.87e-06	5.56e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.85e-06	5.53e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.84e-06	5.51e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.83e-06	5.49e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—CD4—acquired immunodeficiency syndrome	2.82e-06	5.48e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL2—acquired immunodeficiency syndrome	2.81e-06	5.46e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	2.8e-06	5.44e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.79e-06	5.41e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IL6—acquired immunodeficiency syndrome	2.76e-06	5.36e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.7e-06	5.24e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.7e-06	5.24e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.65e-06	5.14e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—IL6—acquired immunodeficiency syndrome	2.65e-06	5.14e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CCR5—acquired immunodeficiency syndrome	2.64e-06	5.13e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.61e-06	5.06e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IL6—acquired immunodeficiency syndrome	2.6e-06	5.06e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.6e-06	5.05e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.59e-06	5.03e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.58e-06	5e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.57e-06	4.99e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IFNG—acquired immunodeficiency syndrome	2.57e-06	4.98e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.55e-06	4.96e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IFNG—acquired immunodeficiency syndrome	2.55e-06	4.95e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.55e-06	4.95e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.52e-06	4.88e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD4—acquired immunodeficiency syndrome	2.48e-06	4.81e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD4—acquired immunodeficiency syndrome	2.47e-06	4.79e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.44e-06	4.73e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.41e-06	4.67e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IFNG—acquired immunodeficiency syndrome	2.4e-06	4.66e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.39e-06	4.63e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.34e-06	4.54e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.34e-06	4.53e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.33e-06	4.53e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.33e-06	4.52e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL6—acquired immunodeficiency syndrome	2.32e-06	4.51e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.32e-06	4.5e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD4—acquired immunodeficiency syndrome	2.32e-06	4.5e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.3e-06	4.46e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.29e-06	4.44e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL6—acquired immunodeficiency syndrome	2.29e-06	4.44e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.29e-06	4.44e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.28e-06	4.42e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL2—acquired immunodeficiency syndrome	2.28e-06	4.42e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL2—acquired immunodeficiency syndrome	2.27e-06	4.4e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—IL6—acquired immunodeficiency syndrome	2.25e-06	4.36e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL6—acquired immunodeficiency syndrome	2.23e-06	4.33e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL6—acquired immunodeficiency syndrome	2.23e-06	4.32e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.15e-06	4.18e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CD4—acquired immunodeficiency syndrome	2.14e-06	4.15e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL2—acquired immunodeficiency syndrome	2.13e-06	4.14e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IFNG—acquired immunodeficiency syndrome	2.1e-06	4.08e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.09e-06	4.06e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.05e-06	3.99e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD4—acquired immunodeficiency syndrome	2.03e-06	3.94e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.02e-06	3.93e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2e-06	3.89e-05	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.99e-06	3.87e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.98e-06	3.84e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.89e-06	3.67e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.89e-06	3.66e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CD4—acquired immunodeficiency syndrome	1.87e-06	3.64e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.87e-06	3.64e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL2—acquired immunodeficiency syndrome	1.87e-06	3.63e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IFNG—acquired immunodeficiency syndrome	1.86e-06	3.61e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.85e-06	3.59e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—acquired immunodeficiency syndrome	1.82e-06	3.54e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.82e-06	3.53e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.81e-06	3.51e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD4—acquired immunodeficiency syndrome	1.8e-06	3.49e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—acquired immunodeficiency syndrome	1.8e-06	3.49e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—acquired immunodeficiency syndrome	1.7e-06	3.31e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.68e-06	3.27e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.67e-06	3.24e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CD4—acquired immunodeficiency syndrome	1.66e-06	3.22e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—acquired immunodeficiency syndrome	1.65e-06	3.21e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2—acquired immunodeficiency syndrome	1.65e-06	3.21e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—acquired immunodeficiency syndrome	1.53e-06	2.96e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.5e-06	2.91e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.48e-06	2.87e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.47e-06	2.86e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.42e-06	2.75e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.38e-06	2.68e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.37e-06	2.66e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.37e-06	2.66e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—acquired immunodeficiency syndrome	1.34e-06	2.6e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—acquired immunodeficiency syndrome	1.33e-06	2.59e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—acquired immunodeficiency syndrome	1.25e-06	2.43e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—acquired immunodeficiency syndrome	1.24e-06	2.4e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.21e-06	2.34e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.18e-06	2.29e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.16e-06	2.25e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—acquired immunodeficiency syndrome	1.16e-06	2.25e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.1e-06	2.14e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—acquired immunodeficiency syndrome	1.1e-06	2.13e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.07e-06	2.08e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.07e-06	2.08e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—acquired immunodeficiency syndrome	1.01e-06	1.97e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—acquired immunodeficiency syndrome	9.72e-07	1.89e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	9.33e-07	1.81e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—acquired immunodeficiency syndrome	8.98e-07	1.74e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.66e-07	1.68e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.11e-07	1.57e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.1e-07	1.38e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.29e-07	1.22e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	5.75e-07	1.12e-05	CbGpPWpGaD
